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Abstract
Identification of new drug targets is vital for the advancement of drug discovery against Mycobacterium tuberculosis,
especially given the increase of resistance worldwide to first- and second-line drugs. Because traditional target-based
screening has largely proven unsuccessful for antibiotic discovery, we have developed a scalable platform for target
identification in M. tuberculosis that is based on whole-cell screening, coupled with whole-genome sequencing of
resistant mutants and recombineering to confirm. The method yields targets paired with whole-cell active
compounds, which can serve as novel scaffolds for drug development, molecular tools for validation, and/or as
ligands for co-crystallization. It may also reveal other information about mechanisms of action, such as activation or
efflux. Using this method, we identified resistance-linked genes for eight compounds with anti-tubercular activity. Four
of the genes have previously been shown to be essential: AspS, aspartyl-tRNA synthetase, Pks13, a polyketide
synthase involved in mycolic acid biosynthesis, MmpL3, a membrane transporter, and EccB3, a component of the
ESX-3 type VII secretion system. AspS and Pks13 represent novel targets in protein translation and cell-wall
biosynthesis. Both MmpL3 and EccB3 are involved in membrane transport. Pks13, AspS, and EccB3 represent novel
candidates not targeted by existing TB drugs, and the availability of whole-cell active inhibitors greatly increases their
potential for drug discovery.
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Introduction
Given the alarming rise of resistance to tuberculosis (TB)
drugs worldwide, the identification of novel drug targets is
critical for the future of TB control [1]. Many attempts to
develop new drugs for infectious diseases have employed a
target-based strategy, for example conducting high-throughput
assays of large compound libraries for inhibition of a critical
enzyme/protein. Recent analyses of large-scale target-based
screening campaigns suggest that this strategy has not been
productive; for example, in a retrospective study of over 70
campaigns conducted at GlaxoSmithKline, only five
compounds have progressed into drug development despite
multiple screens [2]. This lack of success was due to a number
of factors, including lack of whole-cell activity (i.e. cell-wall
permeability) for high-throughput screening leads. In contrast,
whole-cell screening has numerous advantages, since
compounds with demonstrable inhibition of bacterial growth
can be directly identified from large compound libraries. This
approach has the benefit that a genome-wide panel of
essential cellular targets can be evaluated in a single assay;
such a comprehensive approach avoids bias in target selection
and obviates the need for detailed biological characterization of
targets in advance. However, this approach is limited by the
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effort required to define the cellular targets of each compound,
needed to facilitate subsequent medicinal chemistry.
We have developed a scalable platform for the discovery of
drug targets for any pathogenic organism that is based on
combining high-throughput screening (HTS) with whole-
genome sequencing (WGS) of resistant isolates. The method is
not biased by prior expectations of gene essentiality, and
instead is driven by empirical observation of cellular processes
whose inhibition leads to cell death. The approach begins with
a whole-cell screen to identify compounds that inhibit growth.
Bacterial mutants that are resistant to each active compound
are selected in vitro, and deep sequencing is performed to
identify resistance-associated polymorphisms. The contribution
of each mutation to the resistant phenotype is then confirmed
by introducing single point mutations into the parental strain by
phage-recombinase-mediated recombination (i.e.
“recombineering” [3]). Screening coupled with sequencing of
resistant mutants has been used previously on an individual
basis for identifying new targets, such as the F0-F1 ATP
synthase, which was shown to be the target of diarylquinolines
(e.g. Bedaquiline) at Johnson & Johnson [4,5]. The
combination of next-generation sequencing and rapid selection
and identification of resistance mutations we describe enables
this method to be scaled-up effectively to allow for genome-
wide surveys of novel inhibitor-target pairs.
Using this approach, each target is effectively pre-validated
by demonstrating that the chemical inhibition of the protein
leads to cell stasis or death. Furthermore, the inhibitory
compound is by definition whole-cell active, making it a
promising starting point for drug discovery (in that it can
already be shown to gain cell entry). These compounds also
provide a ligand for crystal structure determination of protein-
ligand complexes. Additional information about the mechanism
of action of a whole-cell active HTS hit can be uncovered
through additional proteins implicated in resistance, such as
activators, detoxification proteins, drug efflux pumps, or
proteins affecting cell-wall permeability. The novelty of our
approach is based on the scalability of the process; we have
developed and refined methods for each technique which, in
combination, provide a rapid, concurrent methodology for
target identification that minimizes resource requirements and
can be used for compounds for which there is limited supply.
In this study, resistance-associated mutations were identified
for eight HTS hits with activity against Mtb using the described
method, and the functional significance of the mutations has
been confirmed via recombineering. The resistance-conferring
mutations observed indicate a diverse range of possible
resistance mechanisms. Four genes are essential for bacterial
growth, and these mutations likely alter drug binding to its
target site. Two genes are transcriptional regulators which
might regulate expression of an efflux pump. One is a known
pro-drug activator. Although most mutations consisted of
single-nucleotide polymorphisms or small insertions/deletions,
one compound had the unprecedented effect of selecting for
the insertion of an IS6110 transposon into a specific
susceptibility-conferring gene. Our results in applying this
target identification procedure to Mtb show that it is effective at
discovering resistance-associated genes, including a subset of
candidate drug targets.
Results
To initiate this study, eight compounds with anti-tubercular
activity (Figure 1) were selected from whole-cell screens
against Mtb H37Rv performed at several institutions, including
the National Institutes of Health, the University of Illinois at
Chicago, and Novartis, Inc. High-throughput screening was
carried out in liquid culture (7H9 medium) under aerobic
conditions, using glucose as a carbon source, or in 7H12
medium with palmitate as carbon source. Whole-cell active
compounds were selected from the screens using several
criteria, including potency and chemical-structural properties.
Compound activities were confirmed by evaluating the
minimum inhibitory concentration (MIC99, representing 99%
growth inhibition) in dose-response studies. MICs (on solid
medium) ranged from 0.25 to 12.5 µM (Table 1). The selected
compounds all have drug-like properties [6] in terms of
molecular weight (<500) and logP (<6) (Table 1). Sources of
compound material are listed in Table S1 in File S1.
Resistant mutants of Mtb H37Rv were isolated for each
compound on solid medium using methods optimized for Mtb.
In order to obtain resistant isolates, we plated 107, 108 or 109
cells on several concentrations of each compound above the
MIC (2X, 5X, 10X solid MIC, or 5X and 20X liquid MIC). In
order to conserve compound, which in some cases was
limiting, we used a minimal quantity of agar (3 ml) in 12-well
plates. The combination of compound concentration and CFUs
(colony-forming units) which gave rise to individual resistant
colonies was compound-dependent. For each compound we
performed the isolation protocols 1-3 times. Colonies were
obtained for all compounds. For each compound, we selected
three to four resistant isolates for whole-genome sequencing.
This allowed the comparison of observed genetic
polymorphisms among independent clones. For a subset of the
compounds, the MIC99 of resistant colonies was determined by
serial dilutions of the compound on solid media (plates). For
the remaining compounds, because the amount of material
Table 1. Molecular properties and MIC99 values of inhibitory
compounds against Mtb H37Rv.
compound   MW logP liquid MIC (μM) solid MIC (μM)
1 342 4.68 0.6 2.5
2 444 3.82 1.3 6.25*
3 395 4.15 2.0 6.25*
4 384 2.99 0.7 12.5*
5 399 5.71 0.6 0.25
6 356 4.26 12.5 5.0
7 369 2.65 >20 12.5
8 317 2.53 0.6 1.56*
* These MIC99 values were determined in Mtb strain mc2 7000, which is a
ΔpanCΔRD1 deletion mutant of H37Rv [70], but displays an identical phenotype
and sensitivity to all drugs tested to date.
doi: 10.1371/journal.pone.0075245.t001
New Drug Targets in Mycobacterium tuberculosis
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Figure 1.  Compounds with whole-cell inhibition used for target identification.  
doi: 10.1371/journal.pone.0075245.g001
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was limited, a lower bound for the MIC was determined in liquid
media at several concentrations above the wt MIC and
reported as the highest concentration at which growth was
observed (the MIC could have been even higher than the
highest concentration tested). In each case, resistant mutants
had a shift of at least 4-fold over the relevant wt MIC, except for
compound 1 (Table 2).
Genomic DNA for resistant clones was extracted and
sequenced using an Illumina GenomeAnalyzer IIx (GAIIx). The
samples were sequenced in paired-end mode with a read
length of 36 to 51 bp (with pairs of reads from opposite ends of
~200 bp genomic fragments). Sequencing details for the
individual strains are shown in Table S2 in File S1. Reads were
assembled into complete genome sequences using a
comparative assembly method [7]. The genomes of the
parental strains used (H37Rv stocks from each individual
laboratory) were first sequenced, and these were used as
reference sequences for assembly, to screen out
polymorphisms that are common to the parental strain used.
The depth of coverage varied depending on the sample, but
ranged between 21 and 174 (i.e. mean number of reads
covering each site, averaged over the whole genome). The
completion for each genome was >97.8% (percentage of
4,411,532 sites covered by at least 2 reads), and regions not
covered were primarily restricted to PE_PGRS genes, which
often have low coverage due to high GC content and generally
are not relevant to drug resistance in TB [8]. The mutations
identified in each strain are shown in Table S2 in File S1. The
table includes all polymorphisms that could be identified with
high confidence (where coverage 5X and homogeneity of base
call >70%).
Table 3 summarizes the mutations found in common loci for
each compound. For each compound, mutations could be
identified either at an identical site or within the same gene
among all the resistant mutants. No common mutations were
found in strains resistant to different compounds. In most
cases, each resistant mutant for a given compound had a non-
synonymous substitution in the same gene. In some cases
Table 2. Selection of resistant mutants.
compound   
concentr. used for
selection (μM)
multiple over MIC (solid
media) MIC of mutants (μM)
method used to
determine MIC  
relevant reference MIC (μM)
(from Table 1) multiple over wt MIC
1 12.5 5x 6.3 solid 2.5 2.5x
2 26 4x ≥10 liquid 1.3 ≥7.5x
3 10 1.6x ≥16 liquid 2.0 ≥8x
4 12 1x ≥32 liquid 0.7 ≥46x
5 1.25 5x 2.5 solid 0.25 10x
6 25 5x 50-100 liquid 12.5 ≥4x
7 50 4x >100 solid 12.5 >8x
8 3, 12 2x,10x ≥10 liquid 0.6 ≥16x
For some of the mutants, the MIC99 was determined by serial dilution on solid medium. For the other mutants, the MIC growth was assessed in liquid medium at several
concentrations above the wt MIC, and the highest concentration at which growth was observed is reported, thus representing a lower bound for the MIC (marked as '≥').
doi: 10.1371/journal.pone.0075245.t002
Table 3. Polymorphisms identified in resistant mutants.






1 Rv0283 eccB3 R14L, N24H, -AAC in aa 26 3/3 Yes component of ESX-3 type VII secretionsystem
2 Rv0206c mmpL3 F644L (2), F644C, A677V 4/4 Yes membrane transporter
3 Rv3800c pks13 D1644G,D1607N (3) 4/4 Yes polyketide synthase (mycolic acidbiosynthesis)
4 Rv2572c aspS F526L,T570I (2) 3/3 Yes aspartyl-tRNA synthetase
5 Rv0678  I67S, aa69 +GC, +A at -9 promoter 3/3 No transcriptional regulator of mmpL5/mmpS5efflux pump
6 Rv1685c  IS6110 transposon insertions in aa 96, 101, and 105 3/3 No transcription factor
7 Rv3854c ethA C253R, -T in Q24 , -T in E113 3/3 No monooxygenase (ethionamide activator)
8 Rv0392c ndhA G>C -44 bp upstream 4/4 No NADH dehydrogenase
Essentiality was determined in vitro via transposon mutagenesis analyzed via deep sequencing [9]. These are consistent with earlier analyses of essentiality based on PCR
sequencing of transposon mutants [71].
doi: 10.1371/journal.pone.0075245.t003
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these mutations altered different codons within the same gene,
or occurred in the upstream non-coding region (e.g. putative
promoter mutations -44 bp upstream of ndhA). No large-scale
insertions, deletions, or duplications were detected among
these resistant mutants. Insertion locations of the IS6110
transposon were identified, and were found to be identical to
the 16 sites in H37Rv in all cases except one (Rv1685c, vide
infra).
The essentiality of these genes in vitro was previously
determined by transposon mutagenesis studies using a high-
resolution method based on deep-sequencing that yields data
on insertions at individual TA dinucleotide sites [9]. Four of the
resistance genes identified are known to be essential,
suggesting they are direct targets of the respective inhibitors.
The causes of resistance to each compound are discussed on
an individual basis below.
Recombineering was used to validate the functional
significance of the resistance-associated polymorphisms (Table
4). Mutations identified in resistant mutants were transferred to
the parental strain using the phage Che9c recombination
functions [10], which was optimized for efficient integration of
oligonucleotides into the chromosome of Mtb. The protocol is
designed to select specifically for resistant transformants while
minimizing the risk of selecting oligo-independent resistant
mutants. Using the recombineering plasmid pKM402, which
expresses only the RecT function (the only one required) at
high levels from the Ptet promoter, the rate of oligo-mediated
recombineering is 4 orders of magnitude higher than the
spontaneous rate of mutation, greatly increasing the
confidence in identification of oligo-mediated changes for SNP
verification. In seven of the eight cases, transformants with the
predicted mutations were shown to tolerate higher inhibitor
concentrations than wild-type (producing colonies on plates at
concentrations at which none or a much lower frequency were
observed for no-DNA controls), confirming that the identified
mutations are responsible for conferring resistance.
EccB3
Clones selected for resistance to 1 were found to have MICs
2.5-fold higher than the parental strain (on solid medium). Of
the 3 resistant mutants sequenced, all three had mutations in
eccB3 (Rv0283), including two that caused non-synonymous
amino acid substitutions (R14L, N24H), and one that
introduced a frame-preserving deletion of three nucleotides (-
AAC, deleting amino acid 26). EccB3 is a component of the
ESX-3 type VII secretion system, one of five paralogous
clusters (ESX-1 through ESX-5) in the Mtb genome [11].
Among the five ESX clusters in the TB genome, only ESX-3 is
essential in vitro [9]. ESX-3 had been found to be regulated by
the FurB transcription factor, suggesting that it is involved in
iron or zinc acquisition [12]. Two lines of evidence strongly
suggest that this system is absolutely required for iron and zinc
acquisition. Strains of Mtb [13] and Mycobacterium bovis BCG
[14] in which the native promoters for this locus were replaced
by artificially regulated promoters were unable to grow without
excess iron and zinc. Moreover, a Mycobacterium smegmatis
strain lacking the entire ESX-3 locus and a second iron uptake
system also could not grow in iron-depleted medium [14]. Loss
of ESX-3 was specifically associated with the inability to utilize
a mycobacterial siderophore, mycobactin [14]. Intriguingly,
compound 1 has a pyrazolo(1,5α) pyrimidinone core which
could potentially chelate metal ions or participate in redox
cycling. The precise role of the EccB3 subunit in the ESX-3
secretion complex is unknown. All three mutated residues are
localized in the predicted 73 amino acid cytosolic domain on
the N-terminal side of this protein’s single predicted
transmembrane region. However, recombineering of these
mutations did not yield transformants that were resistant to 1.
The reason for this is unclear, but it might be that special
conditions such as selection on iron-depleted media are
required to successfully obtain resistant transformants.
MmpL3
Four mutants resistant to 2 were found to have mutations in
mmpL3 (Rv0206c), translating to F644L (2), F644C, and
A677C. These mutants had MICs of at least 10 µM (liquid), or
7.5X the MIC of the parental strain (1.3 µM, liquid). MmpL3 is a
membrane transporter in the RND (Resistance-Nodulation-Cell
Division) family, and is predicted by transposon mutagenesis
[9] as well as targeted inactivation by recombination [15] to be
the only essential member of the eleven MmpL gene family of
Mtb. MmpL3 has recently been shown to be the target of
Table 4. Recombineering results.
compound   solid MIC (μM)  
concentration (μM) at which colonies
of transformants were observed, but
not for no-DNA controls
multiple over solid
MIC mutation recombineered colonies observed?
1 3.1   eccB3: R14L, N24H, -AAC in aa 26 no
2 6.25 26 5x mmpL3: F644L,F644C,A677V yes
3 6.25 10 1.6x pks13: D1644G, D1607N yes
4 12.5 32 2.5x aspS:F526L yes
5 0.25 1.0 4x Rv0678: I67S, aa69 +GC, +A at -9 promoter yes
6 5.0 15 3x Rv1685c: frameshifts at same sites as IS6110 insertions yes
7 12.5 100 8x ethA: C253R, -T in Q24 yes
8 1.56 12 8x ndhA:g-44c yes
doi: 10.1371/journal.pone.0075245.t004
New Drug Targets in Mycobacterium tuberculosis
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several small molecules with diverse chemical structures,
including BM212 [16], SQ109 [17] and AU1234 [18]. MmpL3 is
predicted to have two extracellular domains and a central
cytosolic domain, each separated by multiple membrane-
spanning alpha-helices (Figure 2). The biological role of
MmpL3 in the cell is currently unclear. It has been implicated in
transport of iron [19], mycolic acids [18], and trehalose mono-
mycolate [17]. One of the resistance mutations for 2 (A677V) is
located in a membrane-spanning helix between the cytosolic
and C-terminal extracellular domains (see Figure 2), and the
other mutation is in a nearby helix-connecting loop (F644L).
Most of the mutations associated with resistance to BM212 are
conservative (hydrophobic) and are also observed to fall in the
transmembrane helices (including A254V, I296L, I249T, F240L,
L196P, A347V, V689G, in the M. smegmatis ortholog,
MSMEG_0250) [16]. It is possible that these mutations (for
both BM212 and 2) occur in the inner annulus of a pore formed
by the 11 transmembrane helices, and thus influence how
these inhibitory compounds interfere with uptake or efflux of an
essential metabolite. Alternatively, MmpL3 might be acting as
an efflux pump to expel these compounds from the cell and the
observed mutations might enhance affinity. However, it is
noteworthy that the bactericidal activity of BM212 (1.5 µg/ml
MIC for H37Rv) was not influenced by treatment with efflux
pump inhibitors reserpine and verapamil [16], suggesting that
MmpL3 may represent the direct target of this compound, and
that the associated mutations in this gene are not likely to
confer resistance through increased efflux. When the mutations
observed in mmpL3 were independently transferred to the
parental strain via recombineering, colonies of transformants
were observed on plates containing 2 at a concentration of 26
µM (5X the MIC of the parental strain on solid medium),
confirming a causal link to resistance.
Pks13
Compound 3, a benzofuran with an MIC in liquid medium of
2.0 µM, selects for mutations in pks13 (Rv3800c), including
D1607N and D1644G. Resistant mutants had >8-fold higher
MICs than the parental strain (evaluated in liquid medium).
Pks13 is known to be essential for growth in vitro [20,21] and is
a multi-domain polyketide synthase involved in mycolic acid
biosynthesis [22]. The enzyme catalyses condensation of a
C24-C26 long-chain fatty acid to a C40-C60 meromycolate chain,
forming the α-alkyl-β-ketoester branched-chain precursors of
Figure 2.  Location of mutations observed in MmpL3
(based on Tullius et al., 2011).  
doi: 10.1371/journal.pone.0075245.g002
mycolic acids. The enzyme consists of 5 functional modules: a
keto synthase domain, acyltransferase domain, 2 acyl-carrier
protein (ACP) domains, and a thioesterase domain. Pks13 has
been shown to physically interact with FadD32 [22], a fatty
acyl-AMP ligase that is also essential [20], which primes the
acyl substrate for transfer onto one of the ACP domains of
Pks13 via adenylation. The mutations observed in mutants
resistant to compound 3 (D1644G and D1607N) were located
in the C-terminal thioesterase domain (residues 1400-1700),
suggesting that the inhibitor could block de-esterification of the
product (branched mycolic acid precursor). Homology modeling
based on the thiolation-thioesterase (di) domain of E. coli
enterobactin synthase [23] (EntF, PDB: 2roq), the closest
homolog for which a structure is known (25% amino acid
identity), shows these mutations are located in a loop
consisting of a pair of alpha-helices that cover the active site
and form a lid that must open up to accept the pantothenate
moiety of the substrate (Figure 3). Hence the mutations could
affect the lid structure in such a way as to prevent inhibitor
binding in the active site while maintaining native thioesterase
function. Using recombineering to transfer the mutations into a
clean genetic background, colonies were produced on plates
containing 3 at 10µM, a concentration at which no colonies in
the wild-type control were observed, confirming their link with
resistance
AspS
All three mutants resistant to compound 4 harbored
mutations in aspS (Rv2572c), a class II aspartyl-tRNA
synthetase. Compound 4 has a 4-thiazolidinone core, and
other compounds with this core have been found to have
antitubercular activity [24]. Mutants resistant to 4 had MICs in
liquid medium of 32 µM, which is 46-fold higher than the MIC of
the parental strain, 0.7 µM. AspS is predicted to be essential
Figure 3.  Location of mutations in Mtb Pks13, mapped
onto the thiolation-thioesterase domain of E. coli
enterobactin synthase (EntF, PDB: 2roq).  The mutations
occur in a 2-helix lid that closes over the active site.
doi: 10.1371/journal.pone.0075245.g003
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[9], presumably because of its critical role in protein synthesis,
and the lack of an alternative aspartyl tRNA synthetase in the
Mtb genome. The mutations observed in the resistant strains
sequenced were F526L and T570I (2). Interestingly, these
residues occur on the surface of the protein, not in the amino-
acylation active site. Based on the crystal structure of the T.
thermophilus AspS enzyme (1EFW [25]), these residues
(corresponding to residues L515 and T559) both appear near
the dimer interface, approximately 15 Å apart on opposite
subunits (Figure 4). Thus, it is possible that inhibitor binding to
this region disrupts dimerization, which is necessary for the
activity of the yeast homolog [26]. Transfer of the F526L
mutation in aspS to the parental strain via recombineering
allowed colonies to grow on plates with compound 4 at 32 µM
(absence of colonies in the wild-type control well at this
concentration indicated resistance).
Rv0678
Selection for resistance to 5 on plates at a concentration of
5X the solid MIC of H37Rv resulted in mutations in rv0678, a
transcriptional regulator. Three distinct mutations were
observed: a non-synonymous SNP (I67S), a frame-shifting
insertion +GC in residue 69, and an insertion of +A at -9 bp
upstream of the coding region (possibly in the promoter or
ribosome binding site). Resistant mutants had a 10-fold
increase in MIC (2.5 µM) compared to wt (0.25 µM). The two
mutations in the coding region are likely to cause loss-of-
function, and we hypothesize that the upstream mutation would
lead to a decrease in expression. Since Rv0678 is a negative
regulator of MmpL5 and MmpS5 [27], these mutations in
Rv0678 may lead to the increased expression of this putative
transporter. qRT-PCR expression studies of the resistant
mutant to 5 with mutation I67S indicate significant up-regulation
of both Rv0676 (MmpL5) and Rv0677 (MmpS5) (Table S3 in
File S1). Similar mutations in rv0678 (including the +A promoter
mutation at -9 bp upstream, as well as other frameshifts) result
in resistance to certain azole-containing compounds
(antifungals), which is proposed to be due to increased efflux of
the compound [27]. 5 contains an oxazole moiety, and thus
drug efflux by the MmpL5-MmpS5 system is a plausible
mechanism by which mutations in rv0678 confer resistance.
We checked for cross-resistance of these strains to azoles, and
found that one mutant had a slight increase in resistance to
econazole (25 µM MIC, 2.5-fold higher than for H37Rv), though
the other two did not. All three mutations were recombineered
and showed growth in wells with 4X the solid MIC, a
concentration at which no growth was observed for the parental
strain.
Rv1685c
Mutants were selected for resistance to 6 on plates with a
concentration 5X the parental MIC (solid), and all three mutants
sequenced exhibited insertions of an IS6110 insertion
sequence (transposon) in rv1685c. Rv1685c is a transcription
factor whose biological role and regulatory targets are not
known, though it does not appear to be essential in vitro [9].
Rv1685c resides in an operon and is co-expressed with
components of a predicted ABC transporter (Rv1686c,
Rv1687c). Thus resistance to 6 could be due to efflux. The
insertions of the IS6110 transposon were located at distinct but
proximal sites in each of the 3 resistant mutants sequenced: in
amino acids 96, 101, and 105 (in the middle of the 207-residue
protein product). These insertions presumably disrupt the
function of the gene product. These mutants had MICs >4X the
parental MIC (liquid). Since insertion of IS6110 sequences in
target locations is technically challenging, we instead
recombineered both frame-shift and stop-codon mutations at
the same sites where the transposon insertions were observed
in the resistant mutants. In each case, transformants were
observed at concentrations 3 times higher than the solid MIC of
wt H37Rv, confirming that disruption of Rv1685c confers
resistance to 6.
Note that compounds 1 and 6 display a high degree of
chemical similarity, with a purine-like core (pyrazolo(1,5α)
pyrimidinone); yet they clearly select for polymorphisms in
distinct genes. It is possible that they ultimately inhibit the same
target, such as ESX-3, although resistance to compound 6
might be achieved by a distinct mechanism, e.g. efflux.
EthA
Resistant mutants to 7 (an oxadiazole thioether) displayed
greater than an >8-fold shift in MIC (>100 µM) on solid
medium. Similar oxadiazole thioesters have been shown to
have antifungal activity [28]. Three clones were selected for
sequencing. One mutant resistant to 7 was sequenced and
found to have a non-synonymous polymorphism in ethA
(Rv3854c), corresponding to amino acid substitution C253R.
The other two had frame-shifts: -A in codon 24 and -A in codon
113 in ethA. EthA is a non-essential FAD-dependent
Figure 4.  Location of mutations in AspS, based on the T.
thermophilus model (PDB: 1efw).  The peptide chains are
shown as blue and gray ribbons, and the tRNA molecules are
shown as atomic models. The side-chains of residues Leu515
and Thr559, corresponding to the mutations in the Mtb AspS
(F526 and T570), are highlighted in green and are located in
the dimer interface.
doi: 10.1371/journal.pone.0075245.g004
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monooxygenase that is a known activator of the second-line
anti-tuberculars ethionamide, prothionamide and thiacetazone
[29,30,31,32]. Thus, EthA could also activate 7 which contains
a thioether-substituted oxadiazole and may hydrolyze to form
an activated thiocarbonyl that could be oxidatively activated by
EthA similar to ethionamide. However, the C253R mutant was
not found to be cross-resistant to ethionamide. The C253R
substitution and one of the indels (-A in codon 24) were
recombineered, and both showed growth of transformants in
wells at 8X the solid MIC, whereas the untransformed parental
strain did not. Selection and sequencing of additional mutants
and biochemical characterization will be needed to identify the
ultimate target of 7.
NdhA
Mutants resistant to 8, a 2-mercapto-quinazolinone, were
selected on plates with 2X or 10X the solid MIC of the parent.
Four resistant mutants were sequenced, and all four contained
a single nucleotide substitution of G to C located 44 bp
upstream of the coding region of ndhA (Rv0392c). Mutants with
the ndhA:C-44G mutation had liquid MICs of 10 µM (16X the
parental MIC of 0.6 µM). NdhA is a membrane-bound type-II
NADH dehydrogenase which participates in energy
metabolism, regenerating NAD+ via the oxidative
phosphorylation pathway. However, NdhA is found to be non-
essential in vitro and in vivo by transposon mutatgenesis [9,33],
possibly due to redundancy with Ndh, the other type II NADH
dehydrogenase in the Mtb genome (Rv1854c), which is
essential [34]. One mechanism by which this mutation could
confer resistance would be through up-regulation of NdhA
expression, which could cause resistance by binding and
sequestering the compound. Alternatively, it is possible that 8
acts by inhibiting an NADH-dependent target, and the up-
regulation of NdhA might compensate for this by restoring the
intracellular NADH:NAD+ ratio, analogous to a resistance
mechanism for isoniazid [35]. Indeed, we evaluated the
expression level of ndhA in the resistant mutants by qRT-PCR
and found that expression was increased 40- to 80-fold over
H37Rv, while 4 other transcripts (ahpC, sigA, 16S rRNA and
23S rRNA) were unchanged, confirming the hypothesized
effect of this mutation in the upstream regulatory region. It is
also possible the true target might be involved in nucleotide
salvage or synthesis, as other molecules with a mercapto-
quinazolinone core, have been found to bind and inhibit human
purine nucleoside phosphorylase [36]. The ndhA C-44G
mutation was introduced into the parental strain by
recombineering, and was found to increase the resistance to 8,
yielding colonies of transformants when plated on
concentrations up to 12 µM, implying an approximate 8-fold
shift in MIC over the solid MIC of 1.56 µM for the parental
strain.
Discussion
The eight genes identified through this combined HTS/WGS
method represent a range of resistance mechanisms. Based
on essentiality analysis, four genes likely represent direct drug
targets (Pks13, EccB3, AspS, MmpL3). Two are transcription
factors that presumably regulate the expression of another
protein that determines drug susceptibility, and one (EthA) is a
known pro-drug activator, which could plausibly act by
modifying the compound into a toxic metabolite. One of the
targets is implicated in cell-wall biosynthesis (Pks13, synthesis
of mycolic acids). This is not surprising, given the importance of
this pathway (particularly fatty-acid biosynthesis) to the
mycobacterium, and the fact that many existing drugs target
this pathway, including isoniazid and triclosan (which inhibit
InhA [37,38]). Recently, discovery of another inhibitor of Mtb
Pks13 was reported [39], although resistance mutations for that
compound (which is based on a thiophene core) appear in the
N-terminal domain and it appears to inhibit the fatty-acyl-AMP
loading of Pks13. This differs from the probable mechanism of
action of compound 3 in this study, which likely interferes with
the thioesterase activity in the C-terminal domain. Another
target identified (AspS) is involved in protein translation, which
is a common target for many antibiotics. There is precedent for
tRNA synthetase inhibitors as antibiotics, such as mupirocin, a
natural product that is thought to target the Ile tRNA synthetase
in Gram positive bacteria [40], and inhibitors of methionine-
tRNA synthetase that are being developed for treatment of
MRSA infections [41]. The discovery of disruptions of rv1685c
by IS6110 transposition is a novel mechanism of resistance
that is rarely observed in the laboratory in response to selection
against inhibitors. IS6110 transpositions have not, to our
knowledge, been previously reported as a mechanism of drug
resistance in the laboratory. However, IS6110 transpositions
can be induced synthetically under certain stress conditions,
such as microaerophilic environments [42]. Furthermore,
IS6110 insertions in rv1685c have not been previously reported
in clinical isolates of Mtb in association with drug resistance,
although variation in IS6110 insertion locations is observed
among clinical isolates and is frequently used for
epidemiological typing [43]. [42] IS6110 transposition events
were not observed in any of the other mutants we sequenced.
Resistance to at least two of the compounds is likely
mediated though efflux. We observed no mutations directly in
known drug efflux pumps, though resistance to the two
compounds that selected for mutations in transcription factors
(Rv0678 and Rv1685c, for compounds 5 and 6 respectively) is
probably achieved through changes in regulation of
chromosomally-adjacent membrane transporters (as was
shown to be the case for Rv0678). Selection of resistant
mutants in other organisms like Pseudomonas aeruginosa
often leads to up-regulation of drug efflux pumps [44]. This
would be a potential concern for the target identification
approach we describe if mutations in targets were consistently
masked by mutations in drug pumps. However, although Mtb
has a large complement of membrane transporters that could
act as efflux pumps (e.g. 13 RND resistance/nodulation/division
proteins [15]; >30 ABC transporters [45]; and 16 in the MFS
major facilitator superfamily [46]), induction of efflux pump
expression does not seem to be the primary mode of
resistance in Mtb [47,48]. Some drug efflux pumps in Mtb have
been shown to have specificity for known drugs, including
isoniazid (IniABC [49]), tetracycline (Tap, Rv1258 [50]),
rifampicin (P55, Rv1410c [51]), spectinomycin (Stp, Rv2333c
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[52]) and fluoroquinolones (Rv2686c-Rv2688c [53]), though
mutations in these genes or their regulators are typically not
observed in drug-resistant clinical isolates or laboratory-derived
mutants. In order to find the true intracellular targets of
compounds like 5 and 6, it might be necessary to employ
efflux-pump inhibitors such as reserpine or verapamil [54], or to
use deletion mutants (e.g. of pump regulators) during mutant
selection to suppress the occurrence of mutations that act
through up-regulation of the pump, and thus force mutations in
other genes to achieve resistance to the inhibitor. In the case of
compound 6, we noted that, despite the high degree of
chemical similarity to compound 1, they selected for mutations
in different genes. It is possible that they both act in a similar
manner (e.g. somewhere in iron metabolism as we suspect for
1), though there might be multiple mechanisms for overcoming
toxicity, potentially including efflux for 6.
The approach we have described is an unbiased method for
target identification that does not depend on prior expectations
of which genes or pathways might be essential to an organism.
Target-based approaches to drug discovery have been found
to be effective in only a handful of cases (for example, peptide
deformylase inhibitors [55]), but most other target-based efforts
to date have failed, necessitating novel genome-wide methods
for discovering new targets. Despite the fact that the Mtb
H37Rv genome was sequenced over a decade ago, nearly half
of the open reading frames remain annotated as hypothetical
proteins whose functions are unknown, or are in highly
duplicated families (e.g. FadD) where the specific functions and
substrates remain to be elucidated. Intense effort has been
invested in identifying “persistence” targets, or genes that are
specifically essential for maintaining infection, as high-value
targets for drug discovery [56]. The hallmark of TB infection is
the latent (possibly non-replicating) state that a sub-population
of bacilli appear to enter, in which they become more drug
tolerant [57]. Genes implicated in maintaining this state,
ranging from isocitrate lyase (a member of the glyoxylate shunt
[58]) to DosR (regulator of the hypoxic response [59,60]) to
MbtI (mycobactin biosynthesis, iron acquisition [61,62]), have
all been investigated as drug targets, but these efforts have so
far failed to yield effective lead compounds. An approach
based on high-throughput screening starts with inhibitory
compounds and works backwards to determine which proteins
are revealed as vulnerabilities. This approach should greatly
amplify the value of the large volume of high-throughput
screening data for Mtb that has recently been made publicly
available [63,64,65], by finding targets for these compounds.
The optimized techniques and pipeline we have developed
demonstrate that this method can be effectively scaled-up to
identify a broad range of new targets as part of an intensive,
full-scale drug discovery campaign against a pathogen.
Experimental Procedures
High-Throughput Screening
Compounds with whole-cell activity were selected from high-
throughput screens run at several institutions, including the
NIH, the University of Illinois at Chicago, and Novartis, Inc. All
screens used similar conditions. Mtb H37Rv was grown at
37°C in 7H9 medium with glucose as a carbon source, or in
7H12 with palmitate as carbon source. After 2-3 weeks,
cultures were tested for viability using the Microplate Alamar
Blue Assay [66]. Compounds were evaluated at a
concentration of 10 µM. Compounds demonstrating >50%
inhibition were re-tested in dose response studies, and an
MIC99 (99% growth inhibition) in liquid medium was determined.
Selection of Resistant Mutants
Pilot experiments indicated that liquid MIC values did not
necessarily translate directly to work on solid medium.
Therefore, prior to selection, we determined the solid MIC99 for
H37Rv wild type as described [67]. Resistant mutants were
isolated by plating approximately 107, 108, and 109 bacteria (in
100 µl volume) onto 12-well plates containing 2X, 5X and 10X
solid MIC99 of compound, or 5X and 20X the liquid MIC.
Resistant colonies were then re-streaked onto 2X MIC-
containing medium, liquid cultures prepared, and solid MICs
determined alongside wild-type H37Rv. Resistant mutants
were typically isolated within 1-3 attempts of mutant selection
using up to 109 cells. The MIC99 of the selected colonies
resistant to each compound was determined by serial dilution
on solid media (plates). In cases where compound material
was limiting, resistance was evaluated in liquid media at
several concentrations above the wt MIC, reporting the highest
concentration at which growth was observed. This placed a
lower bound on the MIC (the MIC could have been even higher
than the highest concentration tested).
Genome Sequencing and Identification of
Polymorphisms
Genomic DNA from resistant mutants was extracted by using
either the method described in [68] or with ArchivePure DNA
reagents from 5Prime.com. The DNA library was constructed
by using a genomic DNA sample preparation kit (Illumina). The
sample was first fragmented by either nebulization (provided in
Illumina kit) or sonication (Covaris, Inc). The double-stranded
DNA fragments comprised of 3′ or 5′ overhangs were
converted into blunt ends, using T4 DNA polymerase and
Klenow enzyme. Then Klenow Exo- (lacking 3′-to-5′
exonuclease activity) was used to extend blunt ends with an
“A” base, so that the fragments could be ligated to the adaptors
(Illumina TruSeq kit, or NuGen), which have a single 5’ “T”
base overhang. The ligated DNA was size selected on a 2%
agarose gel. DNA fragments of 250-350 bp were excised from
the preparative portion of the gel. DNA was then recovered by
using a Qiagen gel extraction kit and PCR amplified to produce
the final DNA library. Samples were typically multiplexed at
6-12 per lane, and a total of 5 pmol of DNA was loaded onto
each lane of the sequencing chip for cluster generation. φX174
DNA was used as a control.
The sequencer was operated in paired-end mode, collecting
pairs of reads from opposite ends of each fragment. The
sequencing reaction was run for 36-51 cycles (read length in
bp), and images of each tile on the chip were taken in different
wavelengths for exciting each base-specific fluorophore. Image
analysis and base-calling were done by using the Illumina GA
Pipeline software (v0.3), or Off-Line Basecaller (OLB) v1.8. An
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additional read of length 4-7 bp was collected to determine the
nucleotide bar code from the adapter ligation, and these
sequences were used to de-multiplex the reads in each lane
(assign to individual samples).
The reads that were generated for each strain were mapped
against the appropriate reference genome sequence (aligned,
allowing up to 2 mismatches and no gaps), based on the
parental strain from which the mutants were selected
(laboratory-specific variants of H37Rv that we have previously
sequenced [7]). Paired-end constraints were applied by
requiring both reads of a fragment to map to within 500 bp of
each other. Apparent differences (i.e. sites where the
consensus base from overlapping reads differed from the
expected base in the reference sequence), along with sites
where coverage was low or observed bases were
heterogeneous, were identified, and a contig-building algorithm
was used to construct a local ~200 bp sequence spanning the
site to resolve the sites into SNPs versus indels, based on
alignment to the corresponding region in the reference
genome. We systematically searched for evidence of large-
scale deletions (regions >100 bp with <5X coverage, supported
by paired-end information (where pairs of reads map to
locations >300 bp apart that span across the gap region). If
detected, deletions were confirmed by contig-building across
the gap.
Polymorphic sites were compared across multiple mutants
and the sequence of the parent strain. Sites that were
heterogeneous (where multiple bases were observed and the
majority base was observed in <70% of the reads) or sites in
repetitive regions of the genome were screened out, along with
differences that appeared across all mutants regardless of
resistance, possibly reflecting inaccuracies in the genome
sequence of the parental strain. Sites in PE_PGRS genes were
also filtered out, as coverage in many of these GC-rich genes
is often low, and these potentially polymorphic genes are not
essential and not believed to be relevant to mechanisms of
drug resistance.
Positions of insertion of the IS6110 transposon were
determined by identifying pairs of reads where one read
matches the consensus 1353 bp IS6110 sequence and the
other end maps into the genome. These read pairs were
clustered, and the precise insertion coordinates were
determined by contig-building, which were then compared to
the 16 known insertion locations in the standard H37Rv
reference genome.
Recombineering
Phage Che9 RecT-promoted oligo-mediated recombineering
was used to verify the SNPs found in the sequencing of MTb
resistant strains. Rolling cultures of Mtb H37Rv carrying
pNIT::ET (GenBank no. GU459073) [69] were grown at 37°C in
7H9 broth + 30 mg/ml kanamycin to an OD600 = 0.5–0.7.
Isovaleronitrile was added to a final concentration of 1 mM to
induce the recombinase and the cultures were incubated for
eight hours at 37°C. Glycine was then added to a final
concentration of 1.5% and the cultures were further incubated
overnight at 37°C. Competent cells were prepared and
electroporations were performed as previously described [10]
using 500 ng of a 69 bp DNA oligomer to introduce the SNP. In
all cases, a no-DNA control was included and handled in an
identical fashion. Following electroporation, the cell mixtures
were resuspended in 7H9 (up to 1 ml) and allowed to recover
standing overnight at 37°C. Cultures transformed with an oligo,
as well as no-DNA controls, were then plated on 7H10 agar +
OADC containing inhibitory compounds at concentrations 5
and/or 20-fold higher than the reported MIC, and incubated at
37°C for 3-4 weeks. Verification of the SNP was determined by
the presence of resistant colonies on transformation plates
spread with cultures transformed with an oligo, and the
absence (or near absence) of colonies spread with no-DNA
control cultures. The oligo-mediated rate of resistance was
between 5-100 fold higher (depending on the SNP) relative to
the spontaneous rate (i.e., the no-DNA control). Oligo-
dependent resistant colonies were then grown up, the
presence of the SNP was verified by sequencing, and MIC’s
were determined and compared to wild type Mtb. This
procedure was used for verifications of SNPs in mmpL3,
pks13, ndhA and aspS.
A variation of the protocol described above was used for
verification of SNPs in eccB3, rv1685c, rv0678, and ethA. In
this procedure, Mtb cells containing plasmid pKM402, which
expressed the Che9 RecT recombinase under control of the
Ptet promoter, were used for recombineering. This plasmid
promotes recombineering frequencies between 10-3 to 10-4,
orders of magnitudes higher than spontaneous mutation
frequencies (~10-8 to 10-9). Thus, resistance due to SNP
incorporation can be easily distinguished from spontaneously-
induced mutations. The cells were grown as described above,
but were induced with 500 nM anhydrotetracycline (Atc) and
electroporated with 1 µg of the SNP-encoding oligo. In addition,
the cells were co-electroporated with 1 µg of an oligo conferring
resistance to streptomycin (via alteration of the rpsL gene).
Following outgrowth in 5 ml of 7H9 media for 4-5 days, the
cells were subcultured into 5 ml of 7H10 containing 20 µg/ml
sterptomycin and allowed to grow for an additional 5-7 days.
The growth in streptomycin selects for cells that take up DNA,
and allows for enrichment of the unselected (SNP-containing)
oligo. In trial experiments, 5% of cells that become
streptomycin resistance also incorporate the unselected oilgo.
The cultures were then diluted to an Abs600 reading for 0.1,
and 25 µl of cells (~106) were spotted into 12 wells of a 24 well
plate containing 1.5 ml of 7H10 agar containing various
concentrations of the inhibitory compound. The concentration
range of the compound examined spanned the reported MIC
for Mtb H37Rv (from 4-fold lower to 20-fold higher). An oligo-
dependent increase in the observed MIC of the transformation
mixture, relative to a control culture with no DNA added, was
used to validate the SNP as the resistant determinant. As
further verification, oligo-transformed cells appearing in wells at
concentrations above its observed MIC were grown up in 7H9,
the target regions were amplified by PCR, and the presence of
the SNP was verified by sequencing.
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Supporting Information
File S1.  Table S1, Sources of compounds investigated in this
study. Table S2, Sequencing details including read length (all
were paired-end reads), parental strain, depth of coverage
(average number of reads covering each site), completion
(percent of sites covered by at least 2 reads), and list of all
confident polymorphisms observed for each resistant mutant
sequenced. Table S3, qRT PCR studies show that MmpL5 and
MmpS5 are significantly up-regulated in the I67S mutant of
Rv0678. For comparison, expression levels of MmpL5 and
MmpS5 are also shown in two resistant mutants to econazole,
suggesting they share the same mechanism of resistance.
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